Healthcare Policy

In a seminal shift in federal health policy, the Centers for Medicare & Medicaid Services (CMS) has advanced the third cycle of the Medicare Drug Price Negotiation Program, targeting 15 additional high-cost medications for the first time under Medicare Part B.

The Legislative Milestone

Authorized by the Inflation Reduction Act of 2022, this unprecedented initiative marks the culmination of decades of debate over granting the federal government authority to negotiate prescription drug costs. While the first two cycles focused exclusively on retail drugs under Medicare Part D, the 2026 expansion critically includes physician-administered treatments, such as specific oncology therapies and autoimmune biologics, which will see their negotiated maximum fair prices take effect in 2028.

"This requirement was the culmination of years of debate among lawmakers over whether to grant the federal government the authority to negotiate drug prices in Medicare." — KFF Health Policy Analysis

Navigating the Selection Criteria

To qualify for this negotiation, medications must be single-source brand-name drugs or biological products lacking therapeutically equivalent generic or biosimilar alternatives. Furthermore, small-molecule drugs must be at least seven years past their FDA approval date, while biologics must be 11 years past licensure. This statutory window provides manufacturers a period to recoup research and development costs before facing federal price regulation.

CMS calculated total expenditures for qualifying drugs over a recent 12-month period, combining Part B and Part D spending to identify the top 50 candidates in each category. From this pool, the 15 highest-ranked drugs were selected, accounting for a substantial fraction of the $125 billion spent on these specific products in recent fiscal years.

Official Source

As a dedicated social media embed for this specific policy rollout is dynamically managed, readers are directed to the comprehensive original report for exclusive data and statutory context:

Read the full original report on KFF